Log In
BCIQ
Print this Print this
 

C-Amikacin (MAT2501)

  Manage Alerts
Collapse Summary General Information
Company Matinas BioPharma Holdings Inc.
DescriptionOral encochleated formulation of amikacin, a broad-spectrum aminoglycoside antibiotic, developed using lipid-crystal, nanoparticle delivery technology
Molecular Target Ergosterol
Mechanism of ActionCell membrane destabilization
Therapeutic ModalityMacrocycle

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3.5M

0

$1.4M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/30/2015

$3.5M

0

$1.4M

Get a free BioCentury trial today